GoodRx Holdings, Inc. (GDRX) Q2 Earnings and Revenues Lag Estimates

Company Performance - GoodRx Holdings, Inc. reported quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.10 per share, but showing an increase from $0.08 per share a year ago, resulting in an earnings surprise of -10.00% [1] - The company posted revenues of $203.07 million for the quarter ended June 2025, which was 1.03% below the Zacks Consensus Estimate and an increase from $200.61 million year-over-year [2] - Over the last four quarters, GoodRx has not surpassed consensus EPS estimates and has topped consensus revenue estimates only once [2] Stock Performance - GoodRx shares have declined approximately 5.6% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The current Zacks Rank for GoodRx is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.09 on revenues of $203.71 million, and for the current fiscal year, it is $0.38 on revenues of $819.58 million [7] - The trend of estimate revisions for GoodRx was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - The Medical Services industry, to which GoodRx belongs, is currently in the top 30% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8]